Alchemia is involved in the development and
commercialisation of carbohydrate-based therapeutic agents
for human diseases. Alchemia has developed a proprietary
technology for large-scale manufacturing and cost effective
synthesis of carbohydrates. Alchemia's lead compound is a
generic version of a synthetic heparin that is anticipated
to be ready for market in North America by 2008.